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A B S T R A C T
The real or perceived proximity to death often results in a non-ordinary state of consciousness
characterized by phenomenological features such as the perception of leaving the body bound-
aries, feelings of peace, bliss and timelessness, life review, the sensation of traveling through a
tunnel and an irreversible threshold. Near-death experiences (NDEs) are comparable among in-
dividuals of different cultures, suggesting an underlying neurobiological mechanism. Anecdotal
accounts of the similarity between NDEs and certain drug-induced altered states of consciousness
prompted us to perform a large-scale comparative analysis of these experiences. After assessing
the semantic similarity between ≈15,000 reports linked to the use of 165 psychoactive substances
and 625 NDE narratives, we determined that the N-methyl-D-aspartate (NMDA) receptor an-
tagonist ketamine consistently resulted in reports most similar to those associated with NDEs.
Ketamine was followed by Salvia divinorum (a plant containing a potent and selective κ receptor
agonist) and a series of serotonergic psychedelics, including the endogenous serotonin 2A re-
ceptor agonist N,N-Dimethyltryptamine (DMT). This similarity was driven by semantic concepts
related to consciousness of the self and the environment, but also by those associated with the
therapeutic, ceremonial and religious aspects of drug use. Our analysis sheds light on the long-
standing link between certain drugs and the experience of “dying“, suggests that ketamine could
be used as a safe and reversible experimental model for NDE phenomenology, and supports the
speculation that endogenous NMDA antagonists with neuroprotective properties may be released
in the proximity of death.
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1. Introduction
“And one or two people have said to me, and I've said it to myself: That's what death is going to be like. And, oh, what fun it will be!”
Gerald Heard on the psychedelic experience.
Throughout known history, humans have shown a tendency towards modifying their ordinary state of consciousness by con-
suming certain fungi and plant materials (Devereux, 1997; Escohotado, 1999). Naturally occurring molecules that interact with
endogenous neurotransmitters and neuromodulators can induce an ample range of effects, such as sedation, stimulation, euphoria,
modifications in the perception of the environment and the self, and complex and interactive hallucinations (Lewin & Wirth, 1931;
Nichols, 2016; Perrine, 1996). From Paleolithic cave art to contemporary music the ineffability of drug-induced altered states of
consciousness led to artistic expressions attempting to communicate the associated subjective experiences (Devereux, 1997; Shapiro,
1988). Frequently, analogies are made between the experiences elicited by certain psychoactive compounds and other non-ordinary
states of consciousness (e.g. dreams, nightmares, sleep paralysis, mystical experiences, meditative states) (Barrett & Griffiths, 2018;
Kraehenmann, 2017; Luke, 2008; Millière, Carhart-Harris, Roseman, Trautwein, & Berkovich-Ohana, 2018; Sanz, Zamberlan, Erowid,
Erowid, & Tagliazucchi, 2018). Certain psychiatric conditions have been compared (“modeled“) to the acute effects of psychoactive
compounds (Bubeníková-Valesová, Horácek, Vrajová, & Höschl, 2008; Kyzar, Nichols, Gainetdinov, Nichols, & Kalueff, 2017;
Nichols, 2016). Such comparisons are especially common for drugs collectively known as hallucinogens, a class that includes ser-
otonergic psychedelics (the most known example being lysergic acid diethylamide [LSD]), dissociatives (e.g. arylcyclohexalamines
such as ketamine and phencyclidine [PCP]) and deliriants (e.g. Solanaceae plants rich in anticholinergic tropane alkaloids). It is also
documented that dopaminergic stimulants such as methamphetamine can induce psychotic hallucinatory states (McKetin, 2018).
Perhaps the most intriguing of all experiences compared to drug-induced altered states of consciousness is that of “death” or
“dying” (Grof & Halifax, 1977; Leary, Metzner, Ram, & Karma gliṅ, 1966; Strassman, 2001). Such comparison is evident in the
etymology of word “ayahuasca” (“vine of the dead” in the Quechua language), an Amazonian concoction with psychedelic effects
induced by N,N-Dimethyltryptamine (DMT) (Schultes & Raffauf, 2004; Schultes, Hofmann, & Rätsch, 2001). It is documented that the
Tukano and Shipibo people believe that ayahuasca allows a transition towards a state of direct communication with the spirits of the
deceased (Luna, 2011). Certain societies indigenous to North America incorporate peyote (Lophophora williamsii, a cactus containing
the psychedelic molecule mescaline) in their ceremonies to allow a glimpse into their conception of an afterlife (Bailey, 1973). The
Bwiti people native to present-day Gabon employ the bark of Iboga (which contains the potent hallucinogenic tryptamine ibogaine)
in combination with polyrhythmic music to induce “near-death“ trances (Maas & Süster, 2003). In contemporary Western society, the
experiences elicited by natural and semi-synthetic hallucinogens have also been compared to dying, e.g. see the above reproduced
quotation by Gerald Heard, when discussing the LSD experience with psychiatrist Sidney Cohen (Lee & Shlain, 1992). The feeling of
death and rebirth attributed to certain psychedelics has been postulated as a component of their potential therapeutic effect (Grof &
Halifax, 1977). Descriptions of dissociative anesthetics, especially ketamine, abound in comparisons with the experience of dying
(Corazza & Schifano, 2010; Jansen, 1990, 1997a,1997b). Timothy Leary, a key figure in the popularization and subsequent stig-
matization of LSD, referred to ketamine experiences as “experiments in voluntary death” (Jansen, 1997a,1997b). It must be noted
that the comparison between the experiences induced by these drugs and dying occurs at a purely psychological level, since these
substances are very safe under most circumstances (Alberich et al., 2017; Albott et al., 2018; Dos Santos, Bouso, Alcázar-Córcoles, &
Hallak, 2018; dos Santos, 2013; Gasser et al., 2014; Glue et al., 2018; Kyzar et al., 2017; Nichols, 2016; Rabi, 2016; Riva-Posse et al.,
2018).
“Dying” as a non-ordinary state of consciousness can be related to events known as near-death experiences (NDEs), i.e. phe-
nomenological experiences associated with real or perceived proximity to death (Moody, 1976, Greyson, 2008, Sleutjes, Moreira-
Almeida, & Greyson, 2014). The concept and terminology of NDEs were first introduced into the English language by Raymond
Moody over four decades ago (Moody, 1975). The French equivalent “expériences de mort imminente” had already been identified by
the French epistemologist Victor Egger decades before. The first descriptions of NDEs included a set of phenomenological features
that were subsequently refined, ordered and quantified by numerical scales (Moody, 1975, Ring, 1982, Greyson, 1983). These
features include some of the following: leaving the body boundaries (either towards a different space or dimension, or to observe the
body from a third-person perspective, including phenomena such as autoscopy and out-of-body experiences [OBEs]), feelings of
peace and bliss, traveling through a tunnel or void towards a light, sensing the presence of an irreversible threshold, review of past
life events, and communicating with sentient and autonomous entities (Moody, 1975, Owens, Cook, & Stevenson, 1990, Greyson,
1993, Kelly, 2001, Greyson, 2008, Katz, Saadon-Grosman, & Arzy, 2017, Moore & Greyson, 2017, Cassol et al., 2018). While some
authors proposed a certain preferred temporal ordering for these events, recent research failed to detect prototypical sequences in a
large sample of NDEs (Martial et al., 2017). Interestingly, similar phenomenological experiences, termed “NDE-like”, have been
reported in situations where there was no genuine threat to the individuals’ life (e.g. after fainting or a period of anxiety (Facco &
Agrillo, 2012, Charland-Verville et al., 2014)). These experiences raise questions about the extent to which the proximity to death is
involved in the appearance of a subjective NDE phenomenology. In addition, many researchers have independently noticed the
phenomenological overlap between NDEs and the experiences induced by serotonergic and dissociative psychedelics (Jansen,
1997a,1997b, 1989, 1990; Strassman, 2001; Timmermann et al., 2018). Thus, it has been hypothesized that the long-standing
association between these psychoactive compounds and the experience of “dying” could be based on their capacity to emulate NDEs.
The association between drug-induced experiences and NDEs is frequently discussed in terms of anecdotal evidence and first-
person accounts. Direct experimental evidence supporting this association is scarce. Corazza et al. retrospectively compared reports of
36 subjects who experienced NDEs (related to cardiac arrest) with the experiences of 36 subjects under the acute effects of ketamine
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(Corazza & Schifano, 2010). The authors found sufficient commonalities to conclude that ketamine can reproduce at least some
aspects of NDE phenomenology. Recently, Timmermann and colleagues performed a within-subjects placebo-controlled study with
13 participants to test the phenomenological similarities between the DMT state and NDEs (Timmermann et al., 2018). They found
significant differences vs. placebo using numerical scales designed to quantify NDE (Greyson, 1983). Furthermore, the authors
detected a significant overlap between the phenomenological features of DMT-induced experiences and those described by a matched
group who reported a NDE after a life-threatening situation.
The aforementioned studies provide unique and valuable evidence, but also limitations related to the use of structured ques-
tionnaires to quantify and compare highly complex and heterogeneous experiences, as well as biases in the selection of the psy-
choactive compounds to be contrasted with NDEs. Indeed, NDE phenomenology has also been compared to that induced by LSD
(Morse, Venecia, & Milstein, 1989), dextromethorphan (DXM) (Luke, 2008), carbon dioxide (Meduna, 1950), hashish (Siegel, 1984),
5-MeO-DMT (the 5-methoxylated analogue of DMT) (Shulgin & Shulgin, 1997), ayahuasca (orally ingested DMT, enabled by its
combination with β-carbolines present in Baanisteriopsis caapi) (Strassman, 2001), ibogaine (Maas & Süster, 2003), and others. Thus,
the following questions remain open: (1) Is the phenomenological similarity between NDEs and drug-induced experiences highest for
substances within a certain pharmacological class and mechanism of action?; (2) Can this similarity be inferred from unstructured
free narratives, and do they offer insights complementary to the use of structured questionnaires?; (3) Given the heterogeneity in the
events associated with NDEs (e.g. surrounding circumstances, proximity to death, emotional valence attributed by the subject, etc.),
does such heterogeneity reflect on the similarity with the phenomenology of drug-induced states of consciousness?
In the present work we seek to provide an answer to these questions by retrospectively comparing 625 narratives of events
classified as NDEs with a large number of reports (> 15,000) spanning experiences with 165 psychoactive substances of ten different
pharmacological classes. We build upon previous work showing that natural language processing (NLP) tools used to obtain the
semantic similarity between narratives provide an unstructured alternative to quantify the phenomenological similarity of different
reported experiences (Lange, Greyson, & Houran, 2015; Sanz et al., 2018). Finally, we discuss how our results shed light on the
historical association between certain psychoactive compounds and the experience of “dying“, on the possible neurobiological
mechanisms underlying the robust and reproducible phenomenology of NDEs, on the possibility that NDEs are associated with the
release of endogenous neuroprotective agents in the proximity of death, and finally on the possible therapeutic uses of pharmaco-
logically inducing NDEs in the terminally ill.
2. Materials and methods
In the following, we describe the corpus of NDE narratives (“NDE corpus“), the demographics of the experiencers and the known
circumstances at the time of the NDEs, as well as the corpus of free narratives of experiences with psychoactive compounds obtained
from the Erowid Experience Vaults (“Erowid corpus“). We present an overview of the NLP tools applied to the corpora, especially of
latent semantic analysis (LSA) (Landauer, Laham, & Derr, 2004), the core method to quantitatively compare the similarity of the
reported experiences.
2.1. NDE corpus
NDE experiencers were recruited via the Division of Perceptual Studies (University of Virginia Health System, USA) and the GIGA-
Consciousness (Coma Science Group, University of Liège and University Hospital of Liège, Belgium). Completion of the anonymous
questionnaire was voluntary. The NDE corpus consisted of 625 retrospective narratives of NDEs, comprising a total of 623.926 words.
All experiences scored 7 or higher on the NDE Scale (15.2 ± 7), except for 182 accounts which were collected before the devel-
opment of such scale (Greyson, 1983). In those cases, the narratives contained enough detail to suggest they would have scored 7 or
higher if the experiencers had completed the scale. Many narratives included additional information concerning participant demo-
graphics, nature of the circumstances surrounding loss of consciousness during the experience, severity of physical trauma/closeness
to death, and self-assessment of the emotional valence of the experience (using a 3-point Likert scale ranging from −1 pleasant, 0
neutral, to +1 unpleasant). The age of the participants (68% females) at the time of the experience was 31 ± 15 years (7 missing
values), and the age at the time of the study was 52 ± 13 years (2 missing values). Loss of consciousness at time of the NDE was
attributed to head injury in 13% of the cases, to anesthesia/drug use in 30% of the cases, and to cardiac arrest in 10% of the cases
(228 missing values). Severity of physical trauma/closeness to death was rated retrospectively by the experiencers as “not serious“ in
27% of the cases, as “serious“ in 37% of the cases and as involving loss of vital signs in 35% of the cases (209 missing values). The
NDEs were rated as “pleasant“ in 82% of cases, as “neutral“ in 8% of cases and as “unpleasant“ in 9% of cases (279 missing values).
The NDE corpus metadata can be visualized in Fig. 1.
2.2. Erowid corpus
Reports of psychoactive substance use were downloaded from the Erowid Experience Vaults (https://erowid.org/experiences/).
The webpage www.erowid.org is defined as a “member-supported organization providing access to reliable, non-judgmental in-
formation about psychoactive plants, chemicals, and related issues”. Among other resources, it contains a large number (> 20,000) of
curated freely expressed reports associated with the use of different psychoactive substances.
As described in a previous publication (Sanz et al., 2018), we curated the Erowid corpus by performing the following steps: (1)
discarded reports that resulted from the combination of different substances; (2) discarding duplicate reports appearing under more
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than one category; (3) classified the reports in the most specific way unless such specificity dramatically reduced the number of
reports associated with each individual substance; (4) distinguished the reports associated with plant and fungi and their isolated
psychoactive compounds; (5) only included substances with more than 10 reports. This resulted in 165 substances that were
manually classified into the following classes: serotonergic psychedelics, dissociative psychedelics, entactogens, deliriants, de-
pressants/sedatives, stimulants, antipsychotics/antidepressants, oneirogens and others. Some substances were also given a secondary
category due to the complex nature of their effects.
The data in the Erowid corpus is summarized with detail in the supplementary material. Table S1 presents the following in-
formation for serotonergic psychedelics: generic drug names/botanical species, PubChem CID (for molecular compounds) (Hähnke,
Kim, & Bolton, 2018), number of reports and a brief description of the known mechanism of action and the geographic distribution
(for naturally occurring plants, mushrooms and cacti) (Rätsch, 2005). Table S2 contains the same information for dissociatives,
entactogens and deliriants, Table S3 for depressant/sedatives, Table S4 for stimulants, others and oneirogens, and Table S5 for
antipsychotics/antidepressants.
Following previous work, drug categories were determined using a hybrid criterion based on pharmacological action and the
subjective effects induced by the substances. Serotonergic psychedelics (5-HT2A agonists) were grouped based on their mechanism of
action (Nichols, 2016). The category of dissociative psychedelics comprised primarily NMDA antagonists such as the ar-
ylcyclohexylamines ketamine and PCP, but also included substances with other mechanisms of action (i.e. Amanita muscaria
mushrooms) (Wallach & Brandt, 2018). Deliriants were in most cases Solanaceae plants rich in tropane alkaloids (El-Dabbas & Evans,
1982). Entactogen drugs were categorized by their subjective effects (Nichols, 1986). Stimulants included dopaminergic drugs such
as cocaine, amphetamines and modafinil, as well as others of different pharmacological profile; analogously, depressants/sedatives
were defined by their effects on the central nervous system, and included substances such as benzodiazepines as well as natural and
synthetic opioid analgesics (Perrine, 1996). Prescription antidepressants and antipsychotics were grouped together into one category.
Only two plants in the Erowid corpus are consumed primarily for their oneirogen effect (Calea zacatechichi and Silene undulata) (Toro
& Thomas, 2007). Certain substances had a large number of subjective reports, but their relatively unique mechanism of action did
not justify the creation of a new category; such substances were classified as “other” (e.g. Salvia divinorum).
2.3. Corpora preprocessing
The preprocessing of the NDE and Erowid corpora was performed using the Natural Language Toolkit (NLTK, http://www.nltk.
org/) in Python 3.4.6. We applied the following steps: (1) separation into individual words after discarding all punctuation marks
(word repetitions allowed); (2) word lemmatization using NLTK (i.e. conversion to the root from which the word is inflicted); (3)
conversion to lowercase; (4) discarding words containing less than three characters (after lemmatization) (Sanz et al., 2018). Since
texts from the Erowid corpus are likely to be influenced by the nature of the substance being reported, we manually compiled a list of
words including substance names, different slang variations (e.g. “weed“, “coke“), and words relating to the possible routes of
administration (e.g. “smoke“, “snort“, “inject“). These were removed from both the NDE and Erowid corpora. The rationale behind
this “censoring” of the corpora was to retain words describing the experiences elicited by the substances, but not the drugs themselves
nor contextual factors such as the route of administration.
2.4. Latent semantic analysis
We employed an index of semantic similarity between narratives as a proxy of the similarity of the associated altered states of
consciousness (Landauer et al., 2004). The main assumption behind our method is that if two subjects are asked to describe certain
experiences, and both narratives mention the same core concepts with similar frequencies, then it is likely that both narratives reflect
similar subjective experiences. Previous work has established the adequacy of LSA to classify the reported subjective effects of
Fig. 1. Characterization of the NDE corpus metadata. Left: hierarchical pie chart showing the proportion of NDEs related to loss of consciousness
due to head injury, anesthesia/drug use, cardiac arrest, and unknown causes. Each segment of the pie chart is further subdivided according to the
severity of the physical trauma/closeness to death, divided into three categories: not serious, serious illness or injury, and loss of vital signs. The
width of these outer segments is proportional to the average NDE Scale score (Greyson, 1983) of the experiences. Right: Histograms of the age of the
experiencers at the time of the NDE, and at the time their accounts were retrospectively recollected.
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different psychoactive substances (Bedi et al., 2014; Coyle, Presti, & Baggott, 2012), and to compare drug-induced altered states of
consciousness vs. non-ordinary experiences of a different nature (Bedi et al., 2014; Sanz et al., 2018).
As a first approximation, we define a matrix A with T rows (number of terms appearing in the corpus) and D columns (number of
documents, in this case each document corresponds to all the reports of a substance in the Erowid corpus, or to all the narratives in
the NDE corpus). This term-document matrix contains in its i j, entry the number of times the i-th term is mentioned in the j-th
document. Then, it is possible to compute the similarity between documents j1and j2 as the linear correlation between their corre-
sponding columns in the matrix A (i.e. the documents are considered similar if the usage of terms is correlated between documents)2.
A problem with this approach is only counting term occurrences, instead of computing their frequency weighted by how many times
the term occurs within a given document vs. across the whole corpus. Thus, we applied the frequency–inverse document frequency
(tf-idf) transform, as implemented in scikit-learn (www.scikit-learn.org). The entries of the matrix A are determined as the product of
the term frequency and the inverse document frequency. The term frequency is defined as the number of times the term appears in
each document. The inverse document frequency is defined as the logarithmically scaled inverse fraction of the documents containing
the term. To eliminate very frequent/rare terms from the corpus, only those appearing in more/less than 5%/95% of the documents
were retained. Intuitively, the tf-idf transform gives a higher weight to terms that are more specific to a given document, decreasing
the weight based on the number of documents in the corpus that contain such term.
Another difficulty with the first approximation described above is that, for a large vocabulary of terms, the occurrence frequencies
are sparse, i.e. most entries in the matrix A are zero and the linear correlation values of the columns are likely to be very low. By
grouping words that appear in similar contexts as concepts, the number of independent variables used to span the semantic space is
reduced. For this purpose, we applied LSA, a NLP tool based on the hypothesis that words with similar meaning appear with similar
frequency in texts (Landauer et al., 2004). To apply LSA, the term-document matrix obtained using the tf-idf transform was first
decomposed into the product of three matrices using Singular Value Decomposition (SDV) (Huang & Narendra, 1975),
= × ∑ ×A U W . In this decomposition U and V are real unitary matrices and ∑ is a diagonal matrix of singular values ordered by
size. To reduce the dimensionality of the semantic space, only the first k singular values of ∑ were retained, yielding the truncated
matrix ∑k. From this matrix, the rank-reduced term-document matrix is computed as = × ∑ ×
∗A U Wk k k. In the supplementary
material we provide an example of the LSA algorithm applied to a small corpus.
2.5. Principal component analysis and automated component labeling
We applied principal component analysis (PCA) to reduce the term-document matrix into a smaller number of components
capturing topics that recurrently appear in the corpora (using an algorithm based on SVD as implemented in MATLAB 2014). We
considered only the topics represented by the first five components, in terms of explained variance in the tf-idf rank-reduced term-
document matrix. Each component was associated with one coefficient per term in the vocabulary. These coefficients were used to
represent the topics in word cloud format using the website https://wordart.com/.
To avoid the arbitrary naming of the components, for each of them we selected the 20 terms with the largest coefficients, and
queried a large space for the words with the highest semantic proximity. For this purpose we used the Datamuse API (https://www.
datamuse.com/), a word-finding engine based on word2vec (Minarro-Giménez, Marín-Alonso, & Samwald, 2014), an embedding
method using neural networks to map words into a vector space with the constraint that words appearing in similar contexts are also
close in the vector space embedding.
3. Results
3.1. Similarity between NDE and drug-induced experiences
We performed a SVD of the term-document matrix, grouping as single documents all NDE narratives and all reports associated
with the 165 substances in the Erowid corpus. We retained the first 20 singular values; this choice was based on the number of drug
categories included in the corpus, as well as on previous research showing adequate results using the same dataset (Sanz et al., 2018).
The robustness of the results against the choice of this parameter was evaluated and is presented in a latter section.
We obtained the correlation matrix derived from computing all pairwise correlations between the columns of the rank-reduced
term-document matrix ∗A (Fig. 2A). The narratives of substances within the same category tended to display a higher semantic
similarity when compared to those of other categories; this was especially clear for antipsychotics and deliriants. Stimulants and
sedatives presented a smaller degree of within-group semantic similarity. Reports associated with the use of serotonergic and dis-
sociative psychedelics and entactogens presented the highest within-group semantic similarity when considered together, but their
differentiation was difficult. Fig. 2B presents the average semantic similarity values for each substance category, and also includes the
semantic similarity with NDE reports. It is evident upon direct visual inspection that NDE reports show the highest degree of semantic
similarity with narratives of dissociative drug experiences.
We then computed the semantic similarity between NDE narratives and those associated with each single substance. Fig. 3
2 It must be noted that the similarity is measured in terms of word co-occurrences, and not in terms of the frequency of single words. For instance,
the word “fear“ could appear frequently in a report of a frightful experience, but also in a report emphasizing absence of fear. However, the different
co-ocurrence frequencies of “fear“ with other words will increase the semantic distance of the reports.
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presents a ranking of the substances in terms of such similarity. Each circle represents a drug that is color-coded based on its primary
(center) and secondary (border) category. The rectangles in the left/right of the figure zoom into the 20 substances whose reports
present the lowest/highest semantic similarity to NDE narratives. The pie charts indicate the proportion of each drug category in the
top/bottom ranked substances. While the most represented category among the top 20 substances was that of serotonergic psy-
chedelics, the dissociative psychedelic ketamine presented the highest similarity to NDE reports, followed by S. divinorum, and a
series of naturally occurring (L. williamsii, 5-MeO-DMT, Psilocybe spp., DMT, iboga, ibogaine, ayahuasca, mescaline and E. peruviana),
semi-synthetic (LSD) and synthetic (5-AcO-DMT, DPT) serotonergic psychedelics. Other dissociatives that ranked among the top 20
substances were nitrous oxide, PCP and methoxetamine. The only deliriants were the plants of the Datura genus. Conversely, the 20
substances with the lowest similarity to NDE narratives only included one serotonergic psychedelic (2C-T-21), and neither deliriants
nor dissociative psychedelic. Most of the substances were either sedatives or stimulants.
The boxplots in Fig. 4A show the average ranking (in terms of semantic similarity to NDE narratives) for each substance category.
Fig. 2. A. Pairwise document semantic similarity matrix obtained after applying LSA to the term-document matrix and retaining the 20 largest
singular values. B. Matrix containing the average similarity values between all documents in each substance class, including the similarity with NDE
narratives.
Fig. 3. Ranking of psychoactive substances in the Erowid corpus in terms of the similarity of their reported subjective effects to NDE narratives. The
rectangles on the left/right zoom into the top 20 lowest/highest ranking substances. The pie charts indicate the proportion of each primary category
within both rectangles. Substances are represented with circles that are color-coded based on their category (the color of the center/border cor-
responds to the primary/secondary category).
C. Martial et al. Consciousness and Cognition 69 (2019) 52–69
57
Dissociatives ranked first, followed by deliriants and serotonergic psychedelics. Pairwise Wilcoxon signed-rank tests showed that the
mean ranking of dissociative substances was higher than that of all other categories except deliriants. All hallucinogens (e.g. dis-
sociatives, deliriants and serotonergic psychedelics) presented a significantly higher average ranking than sedatives, stimulants and
antipsychotics/antidepressants.
3.2. Lexical and semantic similarities between NDE and drug-induced experiences
We then investigated the lexical and semantic features that related to the similarity between NDEs and reports of drug-induced
experiences. We first ranked the terms based on their frequency of occurrence (obtained after applying the tf-idf transform) both in
NDE and ketamine reports. We also computed the average ranking between both sets of reports, to identify those terms having a high
prevalence in ketamine and NDE reports. Results are shown in Fig. 5. The most common terms in both sets of narratives relate to
perception (“face“, “vision“, “saw“), emotion (“fear“), consciousness and cognition (“reality“, “moment“, “universe“, “understand“,
“consciousness“, “memory“, “explain“, “learn“), the self and others (“own“, “arm“, “self“, “person“, “human“, “everyone“, “others“)
and setting (“door“, “floor“, “inside“, “outside“).
The comparison of the most frequent terms in both sets of experiences suggests shared phenomenological features associated with
an altered state of perception of the self and the environment, and a departure from the everyday contents of conscious mentation.
The application of PCA allowed us to classify these terms into recurrent topics appearing throughout both corpora. Fig. 6A shows
word clouds representing the first five principal components, which cumulatively described more than 60% of the variance in the
data. The terms were weighted by the absolute value of their coefficients in the linear combination required to span each component.
The names of the components were obtained by selecting words with the lowest semantic distance to the 20 most relevant terms in
each component (using a trained word2vec model available in the Datamuse API, https://www.datamuse.com/). The first five
principal components were the following:
1st: “Look/self“, included many of the shared terms between NDE and ketamine experiences (Fig. 5), relating to perception,
consciousness, and setting.
2nd: “Tone/negative“, placed a greater emphasis on negative bodily sensations (i.e. “body load“).
3rd: “Make/stuff“, included terms related to the preparation of natural materials with the purpose of extracting and isolating their
psychoactive compounds.
4rd: “Take/dependency“, included terms clearly related to drug abuse, addiction and associated circumstances.
5th: “Disease/religion“, included terms related to diseases and their medical treatment, as well as others related to ceremonies,
rituals and “spiritual“ healing.
In Fig. 6B we show the projection of each category of drugs into the five principal components, as well as the projection of the
NDE narratives. The radar plots present “fingerprints“ consistent with the known subjective and physiological effects of the drugs. For
instance, serotonergic psychedelics projected almost exclusively into the “look/self“ component, stimulants into the “take/“tone“/
negative“ components (likely a consequence of their medical use and associated dependency“ and “tone/negative“ components, and
antipsychotics into the “disease/religion“ and physical side effects). Deliriants induce profound alterations in consciousness and are
generally prepared from plant materials (e.g. Datura spp., Brugmansia spp.) (El-Dabbas & Evans, 1982), thus having the largest
projections into the “look/self“ and “make/stuff“ components. NDE narratives projected into three different components: “look/self“,
“disease/religion“ and “make/stuff“.
Fig. 4. A. Average substance ranking per category (in terms of the similarity of the reported effects to NDE narratives). Boxplots indicate
median± 25th and 75th percentiles. Lower numbers represent higher semantic similarity (i.e. the highest possible rank is 1, corresponding to
ketamine). B. Pairwise Wilcoxon signed-rank tests for the difference in the semantic similarity to NDE narratives for each pair of drug categories.
Black squares indicate a significant difference (p < 0.05) for the pair of drug categories in the corresponding row and column.
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To visualize the relationship between the semantic similarity of NDEs and the narratives associated with specific psychoactive
substances, we superimposed the radar plots in Fig. 6C. This comparison was done for the projections of NDEs vs. ketamine, DMT,
cocaine and heroin reports. For the first two substances, the similarity with the NDE semantic “fingerprint“ is apparent upon direct
inspection, while for the other two substances obvious differences are manifest, mainly involving their projections into the “take/
dependency“ component.
3.3. Robustness vs. number of singular values retained
The SVDs performed in the previous sections retained the 20 largest singular values. In Fig. 7A we show the correlation coefficient
matrix for pairs of vectors that contain the rankings of the 165 psychoactive substances obtained using a number of singular values
ranging from 5 to 145. We observe that modest to high correlations appeared near the diagonal of the matrix, indicating that small
changes in the number of retained singular values did not dramatically alter the ranking of the substances. The correlations became
more stable as the number of singular values was increased. We also note that two ranking vectors computed using a very different
number of singular values (e.g. 20 vs. 100) compare poorly. In Fig. 7B we investigate the robustness of substance category ranking vs.
number of retained singular values. We observe that consistent results emerged for the highest ranked substances. In other words,
while changing the number of singular values influenced the ranking of substances whose reports did not present a high semantic
similarity to NDE narratives, those substances with a high semantic similarity to NDE narratives remained relatively stable. When
computing the mean similarity across all choices of the number of retained singular values (Fig. 7C), ketamine emerged again as the
substance whose reports presented the highest semantic similarity to those of NDE, followed by a series of substances whose ordering
is similar to that of Fig. 3. From retaining 5–145 singular values, ketamine ranked first in most instances, followed by LSD, ibogaine,
L. williamsii and PCP (Fig. 7D).
Fig. 5. Lexical similarity between NDE and ketamine reports. The upper panel presents the 40 most frequent terms in the NDE narratives, together
with a word cloud representation (word size was weighted by the normalized ranking). The middle panel presents the same information for
narratives of ketamine-induced experiences, while in the bottom panel terms are ordered based on the average frequency across both sets of
narratives.
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3.4. Relationship between semantic similarity and NDE metadata
We understand as “NDE metadata“ all the information that is not contained in the NDE narratives themselves, but informs on the
surrounding circumstances and demographics. In Fig. 8A, we show the mean rating (in terms of NDE narrative semantic similarity)
for each drug category, when comparing to NDEs associated with loss of consciousness due to head injury, anesthesia/drug use, and
cardiac arrest. The mean ranking vs. drug category remained stable across conditions, and resembled that of Fig. 4A. A similar result
is shown in Fig. 8B (proximity to death) and Fig. 8C (emotional valence of the experience). As shown in the pie charts, ketamine
emerged in almost all cases as the drug whose reports presented the highest semantic similarity to NDE narratives. The only exception
Fig. 6. A. Five first principal components, ordered by decreasing explained variance. B. Radar plots showing the projections of the narratives (per
substance category and NDEs) into each of the five principal components. C. Radar plots showing the comparison between the projections of NDE
narratives into the five principal components and those of ketamine, DMT, heroin and cocaine narratives.
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was the comparison with NDEs associated with loss of consciousness induced by cardiac arrest, for which LSD ranked comparably to
ketamine. Statistical analyses (one-way ANOVA) did not detect a significant effect of the NDE metadata on the drug ranking.
3.5. Replication of results with additional censored terms
To evaluate whether our main results depended on the presence of the contextual information in the “make/stuff“ and “take/
dependency“ components, we repeated the analysis after censoring the top 500 most relevant terms of each component. After
applying LSA (retaining the highest 20 singular values), the top ten drugs in terms of the semantic similarity of their written reports to
those of NDEs were the following: ketamine, ayahuasca, S. divinorum, L. williamsii, 5-MeO-DMT, LSD, Cannabis, Psilocybin mush-
rooms, iboga, nitrous oxide. Conversely, the ten least similar were: betel nut, atomoxetine, IAP, triazolam, yohimbe, passion flower,
2C-T-21, etizolam, olanzapine, 2C-T-4.
4. Discussion
Even disregarding processes at the sub-cellular scale and characterizing the ≈1011 neurons as “on/off” binary units, the number of
potential physical states of the brain is astonishing. Such complexity is required to support the highly differentiated nature of
consciousness (Tognoli & Kelso, 2014; Tononi & Edelman, 1998; Tononi, 2012). Given the diversity in the potential contents of
human experience, it is remarkable that those contents can be organized into qualitatively different global states of consciousness.
Even more remarkable is that analogies can be made between a finite set of “altered states”, whose underlying neurophysiological
correlates are seemingly unrelated. Especially interesting are the comparisons between pharmacological and physiological or
spontaneously occurring altered states of consciousness, since such comparisons could inform the development of neurochemical
models for the latter (Luke, 2008; Strassman, 2001).
We addressed the long-standing analogy between the experience of dying and the acute effects of certain psychoactive drugs.
Links between dying, death, a potential existence of afterlife and certain hallucinogenic plants and fungi emerged independently
across different societies, and are also ubiquitous in contemporary psychedelic culture. However, scarce empirical research has been
Fig. 7. Robustness vs. the number of singular values. A. Correlation matrix between the vectors that contain the rankings of the 165 substances (in
terms of the similarity of their associated reports to those of NDE narratives), when computed using different numbers of retained singular values
(from 5 to 145 singular values). B. Semantic similarity to NDE narratives as a function of the number of retained singular values, color-coded by the
category of the drug in each ranking position. Substances with lower rankings were not stable against changes of this parameter, while the top
ranked substances remained relatively stable. C. Substances ranked by their mean semantic similarity to NDE narratives (computed across all
choices of the number of retained singular values, from 5 to 145). D. Pie chart showing the proportion of instances in which a substance ranked first
(among all choices of the number of retained singular values).
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conducted to clarify the nature of this relationship. Unlike other human experiences, dying is difficult to study under controlled
laboratory conditions by means of repeated measurements, which is a necessary condition to demonstrate within- and between-
individual robustness, and to determine a core set of phenomenological features. Lacking a precise definition, the association between
pharmacologically altered states of consciousness and “dying“ could represent the cultural propagation of an originally arbitrary
association (i.e., “meme”) (Dawkins, 2006).
The systematic study of reports of individuals who survived close brushes with death suggests an alternative hypothesis. NDEs
present a common core of robust and reproducible phenomenological features with relatively minor variations in terms of cultural
background (Belanti, Perera, & Jagadheesan, 2008), even though certain features (e.g. life review and tunnel sensations) were shown
to depend on religious beliefs (Kellehear, 1993), and the robustness of NDEs does not necessarily imply a consistent temporal
ordering of the defining phenomenological features (Martial et al., 2017) – although previous works have revealed certain con-
sistencies across cultural backgrounds (Athappilly, Greyson, & Stevenson, 2006) and in terms of temporal ordering (Lange, Greyson,
& Houran, 2004).
This body of empirical evidence supports that near-death is by itself an altered state of consciousness that can be investigated
using quantitative psychometric scales (Greyson, 1983). Two studies followed this approach and compared experiences induced by
ketamine (Corazza & Schifano, 2010) and DMT (Timmermann et al., 2018) to NDE phenomenology, the latter having the merit of
assessing DMT phenomenology under controlled experimental conditions including a placebo. These studies support a significant
overlap between both altered states of consciousness, yet a comparison including a wider range of substances is needed to sys-
tematically evaluate how such overlap depends on the pharmacological mechanism of action of different drugs, as well as on the
neurophysiological changes elicited by them. The use of free narratives of drug-induced experiences presents many limitations (see
below for a discussion), but nevertheless allows a comparison that is massive both in terms of the investigated drugs and the number
of associated reports.
Fig. 8. Similarity between narratives associated with substance use and NDEs of different cause, proximity to death and emotional valence. A.
Semantic similarity between drug category and NDEs associated to loss of consciousness due to head injury, anesthetic agents/other drugs, and
cardiac arrest. The rows of the matrices indicate the number of singular values retained in the SVD decomposition for LSA, and the columns indicate
the drug category (color-coded as in Figs. 3 and 4). The sub-panels include the average ranking per substance category, as well as pie charts showing
the proportion of times that the reports of a given substance presented the highest similarity to those of NDE narratives. B. Same information as in
panel A, but for NDEs separated by the proximity to death (not serious, serious and loss of vital signs). C. Same information as in panels A and B, but
for NDEs separated by the emotional valence attributed by the experiencers (pleasant, neutral, unpleasant).
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The comparison between NDEs and drug-induced experiences associated with an ample range of mechanisms of action offers the
possibility of indirectly evaluating neurochemical models of NDEs. Strassman developed a parsimonious model for NDEs suggesting a
relationship with DMT, a serotonergic psychedelic whose presence is demonstrated in human cerebrospinal fluid (Barker, McIlhenny,
& Strassman, 2012; Strassman, 2001). The author further hypothesized that DMT production primarily occurs in the pineal gland,
given its unique location outside the blood-brain barrier and high concentrations of both serotonin and methyltransferase enzymes
(Barker, Borjigin, Lomnicka, & Strassman, 2013), which are required for in vivo conversion of tryptamine to DMT. However, post-
mortem attempts to isolate DMT from pineal glands were unsuccessful (Strassman, 2001). Regardless of these considerations, both our
analysis and the recent work by Timmermann and colleagues (Timmermann et al., 2018) established that DMT-induced experiences
present a substantial overlap with NDEs, with especially strong associations between DMT-induced near-death type experiences and
mystical-type experiences, and the feelings of “ego-dissolution”, “unitive experience” and “oceanic feeling”. This study also estab-
lished associations between NDE-like DMT experiences and certain personality traits (this association with personality traits is also
known in other types of NDE-like); in agreement with the observation that both NDEs and psychedelic experiences are highly
dependent on contextual factors (Greyson, 1993; Nichols, 2016; Studerus, Gamma, Kometer, & Vollenweider, 2012). Our study
established the similarity of both experiences by means of free narratives. The application of dimensionality reduction techniques
(PCA) revealed discrete components with similar ratings between DMT experiences and NDEs, especially in components related to
alterations in conscious perception of the environment and the self (“look/self”) and therapeutic, mystical and spiritual aspects of the
experience (“disease/religion”). These results are consistent with the use of psychometric scales by Timmermann et al. (2018). We
must note, however, that it has not been established that the numerical ratings extracted from free narratives are equivalent to those
obtained using psychometric scales– even though preliminary analyses have been conducted for the NDE Scale (Lange et al., 2015).
Importantly, our analysis revealed that such commonalities were not specific to DMT experiences, but common to other serotonergic
psychedelics as well. Among the top 20 substances eliciting experiences most similar to NDEs, more than 50% of them were ser-
otonergic psychedelics, including L. williamsii, LSD, 5-MeO-DMT and mushrooms of the Psilocybe genus, all of them ranking higher
than DMT.
A possible biological role for the release of endogenous DMT at times of stress is related to its neuroprotective effects, in par-
ticular, the prevention of cell death due to hypoxia and oxidative stress mediated via σ1 receptor agonism (Frecska, Szabo,
Winkelman, Luna, & McKenna, 2013; Szabo et al., 2016). These effects remain to be demonstrated in humans; furthermore, Nichols
has argued that endogenous DMT production could not reach concentrations sufficiently high to elicit any noticeable changes in
subjective experience (Nichols, 2018). Our analysis revealed that ketamine, a synthetic arylcyclohexalamine dissociative anesthetic,
was associated with narratives most similar to those of NDEs, regardless of the circumstances surrounding the NDEs, the actual
proximity to death and the emotional valence assigned by the experiencers. Ketamine acts by antagonism at the PCP site of glutamate
NMDA receptors. Such antagonism has been shown to prevent cell death due to the excitotoxicity caused by hypoxia (Church, Zeman,
& Lodge, 1988; Rothman & Olney, 1986). Many studies and clinical trials have established that ketamine shows neuroprotective and
neuroregenerative effects in humans, even when administered after onset of cerebral insult, improving the clinical outcomes related
to stroke, brain injury and status epilepticus (Church et al., 1988; Fujikawa, 1995; Hudetz & Pagel, 2010; Marcoux, Goodrich, &
Dominick, 1988). This led Grinspoon and Bakalar (Grinspoon & Bakalar, 1979) and subsequently Jansen (Jansen, 1989,
1997a,1997b) to suggest that an endogenous ketamine-like compound is released at times of stress and is responsible for the re-
markable similarities between ketamine-induced experiences and NDEs. Candidate endogenous agents (“endopsychosins”) (Jansen,
1990) have been found in animal tissues, but are likely complex neuropeptides and their molecular structure remains to be de-
termined (DiMaggio, Contreras, Quirion, & O'Donohue, 1986). Other substances suggested as endogenous neuroprotective NMDA
antagonists are N-acetylaspartyl-glutamate, kynurenic acid and agmatine (Luke, 2008). The role of glutamate in NDEs is further
supported by shared similarity with certain types of epilepsy associated with massive glutamate release (Laureys, Gosseries, &
Tononi, 2016; Morse et al., 1989).
The hypothesis of DMT and endogenous NMDA antagonists as the sole causes of NDEs has received extensive criticism, both in
terms of the associated phenomenology and neurobiological plausibility. NDEs can occur in situations in which the threat is only
apparent or even absent (e.g. NDE-like phenomenology during hypnagogic or meditative states) and brain cells are not under direct
stress (Fenwick, 1997); however, Jansen did not rule out the possibility of an anticipatory NDMA receptor blockade, stating that
“there is no reason to suspect that the NDE mechanism would never be activated spontaneously” (Jansen, 1997a,1997b) – indeed, our
analyses ranked ketamine-experiences as the most similar to NDEs regardless of the proximity of death (Fig. 8B). Furthermore, OBEs
are one of the most salient features of ketamine experiences (Wilkins, Girard, & Cheyne, 2011), which Grinspoon and Bakalar
described as “… becoming a disembodied mind or soul, dying and going to another world. Childhood events may also be re-lived. The loss of
contact with ordinary reality and the sense of participation in another reality are more pronounced and less easily resisted than is usually the
case with LSD. The dissociative experiences often seem so genuine that users are not sure that they have not actually left their bodies“
(Grinspoon & Bakalar, 1979). It has been shown that OBEs are frequent in NDEs associated with cardiac arrest (French, 2005), as well
as in other kinds of NDEs (Charland-Verville et al., 2014), supporting a link to NMDA receptor blockade via an endogenous ketamine-
like compound.
Differences in NDE and ketamine-induced phenomenology have been noted, especially between the generally blissful nature of
NDEs and the potential occurrence of ketamine “bad trips” (Fenwick, 1997; Strassman, 1997). This objection can be countered by
noting that the blissful nature of NDEs may have been overestimated (Greyson & Bush, 1992), that contextual factors (“set and
setting“) play an important role in the emotional valence of NDEs and ketamine experiences (Greyson, 1993; Grinspoon & Bakalar,
1979) and finally noting that the subjective effects elicited by an endogenous NMDA antagonist do not need to exactly match those of
ketamine (unless that antagonist is ketamine itself). In support of the ketamine model, it has been argued that subjects who
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experienced both NDEs and ketamine report a remarkable similarity between both experiences (Jansen, 1997a,1997b); however,
lacking proper quantification, it is difficult not to dismiss this evidence as anecdotal (Strassman, 1997). Further criticism to the
ketamine model is based on the observation that not all individuals in the proximity of death actually report an NDE (Sleutjes et al.,
2014); however, a similar percentage of the population is unable to recall their ketamine experiences (Jansen, 1997a,1997b).
Conversely, neurochemical models based on other serotonergic psychedelics received criticism due to the divergence between typical
psychedelic imagery and the hallucinatory content present during NDEs. Nevertheless, DMT is known to produce more immersive
experiences with intense imagery that can include tunnel-like visions and encounters with seemingly autonomous “entities“
(Strassman, Qualls, Uhlenhuth, & Kellner, 1994; Strassman, 2001). The strong association between ketamine and OBEs is shared with
NDEs, but is less manifest in the case of serotonergic psychedelics, including DMT (Wilkins et al., 2011).
Our analysis included reports from a large number of substances and thus allowed the exploration of drugs whose phenomenology
is not commonly associated with that of NDEs. While on average the phenomenology of substances classified as dissociatives was the
most similar to NDEs (with significantly higher similarity than that of serotonergic psychedelics), reports associated with the use of
deliriants also presented a high semantic similarity to NDE narratives. These comprise plants of the Datura and Brugmansia genera,
which are rich in alkaloids of anticholinergic effect known to induce complex and interactive hallucinations, a general state of
confusion and anterograde amnesia (El-Dabbas & Evans, 1982; Iglesias-Lepine, Mariñosa, Ferrer-Da Pena, & Epelde, 2012). Drug
users frequently lack the insight to identify the imagery as hallucinatory. Analogously, individuals who report NDE are also known to
believe in the reality (i.e. corresponding to appropriate real external stimuli) of the experienced events (Schwaninger, Eisenberg,
Schechtman, & Weiss, 2002) due to the experienced clear sensorium. However, since the tropane alkaloids present in these plants are
toxic, it is possible that the semantic similarity was driven by descriptions of real life-threatening situations.
Similar considerations may apply to Salvia divinorum, a very potent hallucinogen that is considered safe, but is known to be
occasionally smoked by users who believe are consuming cannabis (Vohra, Seefeld, Cantrell, & Clark, 2011). This plant contains
salvinorin A, a highly selective and potent agonist of the κ opioid receptor (Chavkin et al., 2004; Roth et al., 2002) capable of
producing intense visual, auditory, somatic and vestibular distortions (Addy, Garcia-Romeu, Metzger, & Wade, 2015; Sumnall,
Measham, Brandt, & Cole, 2011). The intensity of the experience elicited by this drug relative to cannabis may represent a shock to
unsuspecting users, who could retrospectively report the belief of being close to death. Nevertheless, it is interesting to note that
opiate antagonists (which block the subjective effects of salvinorin A) (Sheffler & Roth, 2003) such as naloxone can increase survival
time in fatal or near-fatal circumstances (Holaday & Faden, 1978), leading to the hypothesis that certain endorphins (mainly beta-
endorphin, known to increase in concentration of bodily fluids of dogs moments before their death) (Sotelo, Perez, Guevara, &
Fernandez, 1995) can mediate NDE-like phenomenology (Carr & Prendergast, 1981). However, beta endorphins present high se-
lectivity for μ opioid receptors, whose activation, unlike κ receptors, is implicated in processes such as analgesia, sedation and
euphoria, but not in the production of hallucinations (Loh, Tseng, Wei, & Li, 1976). Certain endorphins (e.g. dynorphin) bind
preferentially to κ receptors (Chavkin, James, & Goldstein, 1982), but there are no experimental results that link them directly to
NDEs. The endorphin model of NDEs also presents limitations stemming from the fact that agonism at opioid receptors can produce
effects that do not resemble the phenomenological features of NDEs (Sivanesan, Gitlin, & Candiotti, 2017).
It is interesting to note that the PCA decomposition of the narratives yielded similar “fingerprints“ for DMT, ketamine and NDEs
(Fig. 6), in contrast to other two control substances (cocaine and heroin). This was mainly due to the fact that these two hallucinogens
presented a relative high projection into the “look/self“ and “disease/religion“ components. The first likely reflects the departure
from ordinary conscious perception characteristic of these drugs and NDEs (also manifest in the lexical analysis presented in Fig. 5).
With respect to the “disease/religion“ component, both ketamine and DMT (as part of the Amazonian concoction ayahuasca) have
been explored for therapeutic uses, especially for the treatment of major depression (Kyzar et al., 2017; Palhano-Fontes et al., 2018;
Sattar et al., 2018). The presence of words related to spiritual and religious contexts suggests that the potential therapeutic benefits of
these substances appear intertwined with ceremonial use in the Erowid corpus (Dakwar et al., 2014; Niciu et al., 2018). This sug-
gestion is supported by the evidence that dissociative NDEs at the time of trauma may provide some therapeutic benefit in reducing
the risk of full-blown post-traumatic stress disorder (Greyson, 2001). NDEs are known to produce long-lasting effects, some of which
are deemed positive by the experiencers, such as changes in their personal understanding of life, self, and personal relations,
modifications in their social customs as well as in their religious or spiritual beliefs and their interest in material possessions and
social status (Bianco, Sambin, & Palmieri, 2017; Dougherty, 1990; Greyson, 2006; Kellehear, 1990; Parnia, Spearpoint, & Fenwick,
2007; Royse & Badger, 2017). Increased psychological well-being and self-worth have been linked to NDEs (Noyes, 1980). It is
interesting to note that psychedelics were shown to induce similar long-term effects (Forstmann & Sagioglou, 2017; Gasser, Kirchner,
& Passie, 2015; Griffiths et al., 2016; Grob et al., 2011; Lyons & Carhart-Harris, 2018). These commonalities lend support to Kenneth
Ring’s early speculation on the “universality“ of transcendental experiences: “The authenticity of a transcendental experience is revealed
by its transformative effects (…). My reading of the evidence suggests that whether the trigger be a spontaneous mystical experience, a
psychedelic episode, or an NDE, once this core is activated, it begins to unfold and bring about transformation in much the same way, as if an
archetype of transformation were engaged” (Ring, 1988). However, it must also be noted that both psychedelics and NDEs can be
distressing experiences with negative sequelae. The changes in personal beliefs can be sudden and disorienting, and feelings of anger,
depression and estrangement from family and friends have been reported (Duffy & Olson, 2007; Greyson, 1997). There have also been
symptoms of post-traumatic stress disorder (PTSD) associated with NDEs, even though avoidance symptoms are less prevalent,
leading to the suggestion that the positive affect linked to NDE-dissociative episodes mitigate PTSD symptoms that frequently arise
from other dissociative experiences (Greyson, 2001). Overall, it is clear that both NDEs and certain hallucinogenic drugs with similar
phenomenology, such as ketamine and serotonergic psychedelics, can induce long-lasting effects on personality and well-being, but
further research is needed to precisely determine the nature of these effects and their prevalence. Finally, NDE reports also presented
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a significant projection into the “make/stuff“ component, likely representing contextual information and the description of activities
not directly related to the NDEs. Nevertheless, the similarity with the reports of ketamine-induced experiences remained the highest
even after censoring the 500 most relevant terms of the “make/stuff“ and “take/dependency“ components.
Neurochemical models of NDEs can be theoretically attractive; however, we must emphasize that the analyses conducted in the
present work neither validate nor refute these models, since they are based on retrospective reports and no physical examinations of
the subjects at the time of the reported NDEs were performed. Regardless of the validity of different neurochemical models of NDEs, a
very interesting question was posed by R. Strassman: “if so, so what?“ (Strassman, 1997). In other words: even if the validity of one of
these models is confirmed, why is neuroprotection linked to substances such as ketamine-like compounds and/or DMT, which are also
known to elicit an altered state of consciousness frequently characterized by feelings of bliss and transcendence? Why is neuro-
protection by endogenous substances not associated with unconsciousness, or with feelings of distress and aversion? It has been
shown that decreased fear of death can be a long-term consequence of NDEs (Greyson, 2007a,2007b); thus, NDEs seemingly lack
adaptive value. However, this conclusion relies on the assumption that decreased fear of death leads to less caution or increased risk-
taking behavior. Also, it could be argued that elderly individuals are more likely to experience health problems leading to NDEs, and
that feelings of aversion towards death could result in the prolonged competition for resources with individuals who have more
potential to reproduce. Furthermore, NDE-dissociative episodes might mitigate PTSD symptoms linked to other dissociative ex-
periences (Greyson, 2001) and NDE experiencers seem to endorse more anti-suicidal attitudes as compared to non-NDE experiencers
who have come close to death (Greyson, 1993), thus adding support to the potential adaptive value of these experiences. In any case,
drugs that mimic NDE phenomenology might also reduce death-related anxiety, suggesting a potential therapeutic use for the
terminally ill. Evidence exists that certain drugs whose reported subjective effects present a high semantic similarity to NDE reports
can alleviate end-of-life anxiety in patients with advanced stage cancer, i.e. psilocybin, LSD and ketamine (Griffiths et al., 2016; Grob
et al., 2011; Kolp, 2007).
Given the nature of our analyses, our discussion is biased towards the discussion of neurochemical models of NDEs. However,
unless direct empirical evidence is obtained, we can only affirm that the reported phenomenology of certain drugs is similar to that of
NDEs, and that those drugs could be effective tools for the safe and temporary induction of NDE-like altered states of consciousness in
controlled laboratory settings. It is nevertheless certain that these laboratory-induced NDEs may be a mere “reflection” of “authentic”
NDEs. Like all models, those based on the effects of psychoactive drugs present limitations. For instance, certain effects of sub-
anaesthetic doses of ketamine are not among the features that characterize NDEs, arguing against the reductionist explanation of
NDEs as a consequence of NMDA receptor blockade (Adler et al., 1999; Dillon, Copeland, & Jansen, 2003). Other models have been
proposed that are not directly related to endogenous psychoactive compounds, but to alterations in neural activity in certain brain
areas, primarily in temporal lobe regions (Britton & Bootzin, 2004; Saavedra-Aguilar & Gómez-Jeria, 1989). Multifactorial ex-
planations for NDE phenomenology have also been proposed. Mobs and Watt argued that each “classic“ feature of this phenom-
enology can be explained via a different mechanism, e.g. awareness of being dead as a form of Coward syndrome, OBEs as a failure to
integrate multisensory information, the perception of a tunnel of light as a consequence of retinal ischemia, etc. (Mobs & Watt, 2011).
However, it has been pointed out by Greyson and colleagues that this article only accounted for those features that could be explained
by the authors, while ignoring other features that are regarded as the most defining for NDEs (Greyson, Holden, & van Lommel,
2012). Furthermore, these alternative models must also be understood as speculative, given the lack of experiments performed at
time of reported near death. Few experiments have investigated the neurophysiological changes associated with the ceasing of vital
functions. Most strikingly, a surge of coherent high frequency (gamma,> 25Hz) oscillations preceding isoelectric activity has been
demonstrated both in humans and animal models (Borjigin et al., 2013; Chawla et al., 2017). However, Greyson and colleagues
provided a series of arguments against the interpretation of these short surges of “hyperactivity“ as neural correlates of NDEs
(Greyson, Kelly, & Dunseath, 2013). It is nevertheless important to note that serotonergic psychedelics such as LSD and psilocybin
result in broadband reductions of brain oscillations (Carhart-Harris et al., 2016; Muthukumaraswamy et al., 2013), while ketamine
enhances gamma oscillations in parietal and cingulate cortices and medial frontal theta oscillations, and decreases occipital, parietal
and anterior cingulate alpha power (Lazarewicz et al., 2010; Muthukumaraswamy et al., 2015). While these results suggest com-
monalities (alpha power decreases) and divergences (gamma power increases) between the spectral changes elicited by ketamine and
serotonergic psychedelics, muscle artifacts are known to heavily affect high frequency bands under the effects of the latter
(Muthukumaraswamy, 2013), and increased gamma oscillations have been reported for ayahuasca and LSD (Muthukumaraswamy &
Liley, 2018; Sattar et al., 2015, Schenberg et al., 2015). It is therefore difficult to compare the spectral changes elicited by ser-
otonergic psychedelics and ketamine, and those recorded during the cease of vital functions.
Our study presents both advantages and limitations stemming from the use of a large number of retrospective narratives. In both
cases, these narratives rely on the memory of the event. The time between the occurrence of the NDEs and participation in the study
averages approximately two decades (Greyson, 2007a,2007b). Reports of subjective effects from Erowid Experience Vaults are likely
closer to the time of substance use, but present several limitations of their own. While substantial relevant data was available for the
participants of the NDE study, demographical information is not commonly available for Erowid users. Reports could be con-
taminated by expectation effects, and most lack laboratory verification of the identity and dose of the consumed substances, which
may be even unknown to the users reporting the experiences. Dose could bias the results if subjects consumed higher doses of
ketamine compared to those of serotonergic psychedelics such as LSD and psilocybin, resulting in dissociation and feelings of dis-
embodiment only for the latter. However, DMT is known to produce these effects at relatively low doses when smoked or ad-
ministered intravenously (Strassman et al., 1994; Winstock, Kaar, & Borschmann, 2014), and ketamine reports still presented a higher
semantic similarity to those of NDEs than the DMT reports. Another limitation is the relative cultural homogeneity of the population.
However, currently no other sources of data exist that include a large number of reports for an equally large number of substances.
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Present-day legislation, as well as ethical concerns, contribute towards the unfeasibility of obtaining such information under con-
trolled laboratory conditions (Nutt, King, & Nichols, 2013). While the reports in the Erowid corpus could be affected by a number of
different confounds, the amount of data might be sufficiently high to expect the detection of a meaningful signal in spite of un-
controlled sources of noise (Halevy, Norvig, & Pereira, 2009).
5. Conclusion
In conclusion, we have systematically compared the semantic similarity of reports associated with the use of psychoactive
compounds and NDE narratives, and found evidence that ketamine (and to a lesser extent different serotonergic psychedelics and
deliriant alkaloids) can produce an altered state of consciousness resembling near-death. With the available experimental data, it is
neither possible to corroborate nor refute the hypothesis that the release of an endogenous ketamine-like neuroprotective agent
underlies NDE phenomenology. However, our results do provide evidence that ketamine, as well as other psychoactive substances,
result in a state phenomenologically similar to that of “dying“ (understood as the content of NDE narratives). This could have
important implications for the pharmacological induction of NDE-like states for scientific purposes, as well as for therapeutic uses in
the terminally ill as means to alleviate death anxiety. We believe that the development of evidence-based treatments for such anxiety
is a cornerstone of a more compassionate approach towards the universal experience of transitioning between life and death.
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